HomeAuthorsPosts by Sam Atkinson

Sam Atkinson

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge in profit for the third quarter ended May 31, 2026. This performance marks a decisive shift from a period of recovery toward a new phase of resilient growth in the...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the country grapples with a growing burden of non-communicable diseases (NCDs), particularly diabetes and chronic kidney disease. Recent estimates show that one-in-six Malaysians has diabetes, while one-in-seven is at risk of chronic...
spot_img

Keep exploring

SGX-LISTED COMPANIES

From Food Processing To Japanese Real Estate – Yamada Green Resources Q2 FY2026

Introduction: When a regional property market cools, standard portfolios often face terminal stagnation. However,...
SGX-LISTED COMPANIES

EuroSports Global Bets Big On Electric Bikes In Q3 FY2026

Introduction: The Luxury Paradox In an era defined by Singapore’s aggressive 2023 luxury vehicle tax...
SGX-LISTED COMPANIES

Hafary Holdings FY2025 US Pivot & Inventory Gamble

From Local Showrooms to Global Strength: 5 Surprising Lessons from Hafary’s Record FY2025 The "Renovation...
SGX-LISTED COMPANIES

Chuan Hup’s $15M Australian Windfall In 1H FY2026

Harvesting the Outback In a market defined by persistent volatility and shifting geopolitical tides, investors...
SGX-LISTED COMPANIES

Can GRP Ltd’s 1H FY2026 AI Pivot Outrun Its Legacy Hurdles?

Navigating the "Messy Middle" of Corporate Transformation How does a traditional industrial player, long associated...
SGX-LISTED COMPANIES

Why British & Malayan Holdings HY2025 Loss Masks A High-Growth Pivot

The Strategic Deficit In corporate finance, a net loss is usually a red flag—a signal...
SGX-LISTED COMPANIES

Asian Micro Sold Assets To Wipe Out 1H FY2026 Losses

Is Asian Micro’s Massive Share Dilution a Lifeline or a Warning? Why Small Moves Matter In...
SGX-LISTED COMPANIES

What’s Driving CapitaLand Integrated Commercial Trust’s Record FY2025 Growth?

The Strategic Pivot In the world of institutional investing, size is often viewed as a...
SGX-LISTED COMPANIES

Why First REIT’s FY2025 ‘Decline’ Is A Strategic Rebirth

The IDR Ghost and the $213M Wall In the high-stakes arena of global real estate,...
SGX-LISTED COMPANIES

How CapitaLand Ascendas REIT Is Future-Proofing Your Investment – FY2025

5 Impactful Takeaways from CapitaLand Ascendas REIT’s 2025 Results Introduction: The Complexity of Growth In the...
SGX-LISTED COMPANIES

SGX 1H FY2026 Breaks Records! Why This Is Their Best Year Ever

The US$180 Billion Pivot: How Singapore’s Multi-Asset Fortress Redefined the Exchange Model In a global...
SGX-LISTED COMPANIES

One Hutchison Port Booms While Another Crashes In FY2025

Navigating Global Turbulence: 5 Surprising Takeaways from HPH Trust’s 2025 Financial Results Introduction: The Global...
Load more

Latest articles

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...